U. BUFFALO (US) — A tiny piece of a critical receptor that fuels the brain shows promise as a new drug target for Alzheimer’s and other neurodegenerative diseases.
“This is the first time that this site has been shown to be useful as a drug target,” says Gabriela K. Popescu, associate professor of biochemistry at the University at Buffalo.
“If we could find a drug that attaches itself to this site and locks together NMDA (N-methyl-D-aspartate) receptor subunits, that would be huge for fighting disability from stroke and Alzheimer’s and other neurodegenerative diseases.”
Published in Nature Communications, the research focuses on the brain’s receptors for the neurotransmitter glutamate, which is implicated in these diseases as well as in other conditions, such as glaucoma.
The two main glutamate receptors in the brain are NMDA and AMPA receptors, both of which play critical roles in human learning and memory. Both types of receptors are made of four subunits and within each receptor these subunits are organized in pairs called dimers.
Because these receptors are so similar in structure, Popescu explains, it was assumed that they function in much the same way.
“But when we altered the dimer interface, the site where two subunits come together within each pair, we found that the NMDA receptor works just the opposite of the way that the AMPA receptor works,” she says. “Cementing this interface in AMPA receptors leads to more activity, whereas we found just the opposite to be true in NMDA receptors.”
By locking the subunits together, researchers were able to markedly reduce NMDA activity and, subsequently, substantially reduce the amount of calcium that enters neurons in response to the neurotransmitter glutamate.
Calcium overload due to overactive NMDA receptors is what eventually kills off neurons, Popescu explains, leading to the symptoms that occur after a stroke, and in Alzheimer’s and other neurodegenerative diseases.
“The fact that by cross-linking the subunits, we could so dramatically reduce NMDA receptor activation demonstrates, for the first time, the tantalizing possibility that we may be able to develop new therapies that can much more effectively treat, or even one day prevent, some of these devastating diseases, like Alzheimer’s and stroke.”
And, because each type of NMDA receptor has a slightly different dimer interface, this finding represents a new opportunity for rationally designing drugs that would preferentially inhibit only a select population of NMDA receptors in the brain, thus reducing the possibility of side effects.
Currently, the Alzheimer’s drug called Namenda, one of the only existing pharmaceuticals that inhibit the NMDA receptor, targets a different site within the receptor.
“If a new drug could be developed to target the dimer interface, which we discovered to be inhibitory, it would allow more specific effects than current drugs,” explains Popescu. “That’s because at this particular interface, the interactions between these subunit interfaces are more precise than those currently being targeted.”
Funding for the work was provided by the NIH National Institute of Neurological Disorders and Stroke.
More news from University at Buffalo: http://www.buffalo.edu/news/